Effect of Tocilizumab on Disease Activity in Patients With Active Polymyalgia Rheumatica Receiving Glucocorticoid Therapy: A Randomized Clinical Trial.

Date publication

septembre 2022

Journal

JAMA

Auteurs

Membres identifiés du Cancéropôle Est :
Pr GOTTENBERG Jacques-Eric , Pr TOUSSIROT Eric

Tous les auteurs :
Devauchelle-Pensec V, Carvajal-Alegria G, Dernis E, Richez C, Truchetet ME, Wendling D, Toussirot E, Perdriger A, Gottenberg JE, Felten R, Fautrel BJ, Chiche L, Hilliquin P, Le Henaff C, Dervieux B, Direz G, Chary-Valckenaere I, Cornec D, Guellec D, Marhadour T, Nowak E, Saraux A

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/36125471

Résumé

Few treatments are available for patients with glucocorticoid-dependent polymyalgia rheumatica. IL-6 antagonists may reduce disease activity in patients with active glucocorticoid-dependent polymyalgia rheumatica.

Référence

JAMA. 2022 09 20;328(11):1053-1062